title: Benefits exceed risks of newer antidepressant medications in youth--maybe not.
authors.affiliation: Translational Neuroscience, Merck Research Laboratories, North Wales, Pennsylvania, USA. william_potter@merck.com
authors.forename: W Z
authors.initials: WZ
authors.lastname: Potter
mesh_terms: D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013405:Suicide
chemical_list: D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors